CARTA AL DIRECTOR
Consideraciones respecto a ezetimiba y deterioro renal
Considerations for ezetimibe and renal impairment
Vicente Pallarés-Carrataláa,b,
, Belén Vizcaíno-Castilloc, José Luis Górriz-Teruelc,d
Autor para correspondencia
a Medicina Familiar y Comunitaria, Unidad de Vigilancia de la Salud, Unión de Mutuas, Castellón, España
b Departamento de Medicina, Universitat Jaume I, Castellón, España
c Servicio de Nefrología, Hospital Universitario Dr. Peset, Valencia, España
d Departamento de Medicina, Universidad de Valencia, Valencia, España
Leído
9507
Vecesse ha leído el artículo
1235
Total PDF
8272
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 26 | 2 | 28 |
| 2025 11 | 168 | 29 | 197 |
| 2025 10 | 141 | 30 | 171 |
| 2025 9 | 130 | 21 | 151 |
| 2025 8 | 150 | 19 | 169 |
| 2025 7 | 183 | 10 | 193 |
| 2025 6 | 163 | 19 | 182 |
| 2025 5 | 164 | 16 | 180 |
| 2025 4 | 170 | 12 | 182 |
| 2025 3 | 133 | 9 | 142 |
| 2025 2 | 89 | 11 | 100 |
| 2025 1 | 101 | 10 | 111 |
| 2024 12 | 78 | 10 | 88 |
| 2024 11 | 124 | 6 | 130 |
| 2024 10 | 133 | 3 | 136 |
| 2024 9 | 114 | 5 | 119 |
| 2024 8 | 113 | 3 | 116 |
| 2024 7 | 93 | 7 | 100 |
| 2024 6 | 72 | 11 | 83 |
| 2024 5 | 95 | 6 | 101 |
| 2024 4 | 75 | 2 | 77 |
| 2024 3 | 85 | 9 | 94 |
| 2024 2 | 82 | 18 | 100 |
| 2024 1 | 106 | 23 | 129 |
| 2023 12 | 69 | 14 | 83 |
| 2023 11 | 106 | 18 | 124 |
| 2023 10 | 118 | 16 | 134 |
| 2023 9 | 70 | 5 | 75 |
| 2023 8 | 70 | 7 | 77 |
| 2023 7 | 64 | 4 | 68 |
| 2023 6 | 56 | 3 | 59 |
| 2023 5 | 81 | 9 | 90 |
| 2023 4 | 82 | 6 | 88 |
| 2023 3 | 99 | 4 | 103 |
| 2023 2 | 74 | 3 | 77 |
| 2022 1 | 62 | 3 | 65 |
| 2022 12 | 59 | 7 | 66 |
| 2022 11 | 71 | 7 | 78 |
| 2022 10 | 55 | 8 | 63 |
| 2022 9 | 61 | 22 | 83 |
| 2022 8 | 66 | 12 | 78 |
| 2022 7 | 76 | 13 | 89 |
| 2022 6 | 43 | 9 | 52 |
| 2022 5 | 473 | 15 | 488 |
| 2022 4 | 62 | 16 | 78 |
| 2022 3 | 80 | 11 | 91 |
| 2022 2 | 61 | 4 | 65 |
| 2021 1 | 79 | 10 | 89 |
| 2021 12 | 48 | 10 | 58 |
| 2021 11 | 78 | 11 | 89 |
| 2021 10 | 138 | 19 | 157 |
| 2021 9 | 80 | 7 | 87 |
| 2021 8 | 78 | 5 | 83 |
| 2021 7 | 38 | 8 | 46 |
| 2021 6 | 59 | 10 | 69 |
| 2021 5 | 47 | 11 | 58 |
| 2021 4 | 102 | 31 | 133 |
| 2021 3 | 110 | 10 | 120 |
| 2021 2 | 45 | 5 | 50 |
| 2020 1 | 60 | 8 | 68 |
| 2020 12 | 55 | 6 | 61 |
| 2020 11 | 56 | 11 | 67 |
| 2020 10 | 38 | 6 | 44 |
| 2020 9 | 51 | 7 | 58 |
| 2020 8 | 50 | 12 | 62 |
| 2020 7 | 29 | 15 | 44 |
| 2020 6 | 37 | 14 | 51 |
| 2020 5 | 27 | 10 | 37 |
| 2020 4 | 20 | 4 | 24 |
| 2020 3 | 22 | 7 | 29 |
| 2020 2 | 36 | 3 | 39 |
| 2020 1 | 38 | 6 | 44 |
| 2019 12 | 64 | 4 | 68 |
| 2019 11 | 20 | 5 | 25 |
| 2019 10 | 34 | 7 | 41 |
| 2019 9 | 40 | 1 | 41 |
| 2019 8 | 23 | 3 | 26 |
| 2019 7 | 26 | 14 | 40 |
| 2019 6 | 71 | 20 | 91 |
| 2019 5 | 207 | 57 | 264 |
| 2019 4 | 57 | 22 | 79 |
| 2019 3 | 12 | 6 | 18 |
| 2019 2 | 26 | 10 | 36 |
| 2019 1 | 10 | 5 | 15 |
| 2018 12 | 8 | 5 | 13 |
| 2018 11 | 8 | 6 | 14 |
| 2018 10 | 28 | 20 | 48 |
| 2018 9 | 17 | 6 | 23 |
| 2018 8 | 13 | 1 | 14 |
| 2018 7 | 5 | 2 | 7 |
| 2018 6 | 6 | 1 | 7 |
| 2018 5 | 11 | 4 | 15 |
| 2018 4 | 6 | 2 | 8 |
| 2018 3 | 8 | 1 | 9 |
| 2018 2 | 1 | 1 | 2 |
| 2018 1 | 3 | 0 | 3 |
| 2017 12 | 11 | 3 | 14 |
| 2017 11 | 4 | 2 | 6 |
| 2017 10 | 7 | 2 | 9 |
| 2017 9 | 4 | 1 | 5 |
| 2017 8 | 26 | 1 | 27 |
| 2017 7 | 8 | 1 | 9 |
| 2017 6 | 13 | 3 | 16 |
| 2017 5 | 9 | 2 | 11 |
| 2017 4 | 11 | 5 | 16 |
| 2017 3 | 15 | 47 | 62 |
| 2017 2 | 14 | 7 | 21 |
| 2016 1 | 15 | 1 | 16 |
| 2016 12 | 24 | 6 | 30 |
| 2016 11 | 44 | 4 | 48 |
| 2016 10 | 41 | 5 | 46 |
| 2016 9 | 47 | 2 | 49 |
| 2016 8 | 28 | 10 | 38 |
| 2016 7 | 29 | 1 | 30 |
| 2016 6 | 37 | 21 | 58 |
| 2016 5 | 29 | 6 | 35 |
| 2016 4 | 32 | 6 | 38 |
| 2016 3 | 40 | 6 | 46 |
| 2016 2 | 39 | 10 | 49 |
| 2015 1 | 33 | 7 | 40 |
| 2015 12 | 20 | 10 | 30 |
| 2015 11 | 36 | 9 | 45 |
| 2015 10 | 38 | 9 | 47 |
| 2015 9 | 31 | 4 | 35 |
| 2015 8 | 65 | 16 | 81 |
| 2015 7 | 233 | 29 | 262 |
| 2015 6 | 318 | 43 | 361 |
Mostrar todo
